We have advocated the idea of agonist therapy for treating cocaine addiction. This strategy involves administration of stimulant-like medications (eg, monoamine releasers) to alleviate withdrawal symptoms and prevent relapse. A major limitation of this approach is that many candidate medicines possess signifi cant abuse potential because of activation of mesolimbic dopamine (DA) neurons in central nervous system reward circuits. Previous data suggest that serotonin (5-HT) neurons can provide an inhibitory infl uence over mesolimbic DA neurons. Thus, it might be predicted that the balance between DA and 5-HT transmission is important to consider when developing medications with reduced stimulant side effects. In this article, we discuss several issues related to the development of dual DA/5-HT releasers for the treatment of substance use disorders. First, we discuss evidence supporting the existence of a dual defi cit in DA and 5-HT function during withdrawal from chronic cocaine or alcohol abuse. Then we summarize studies that have tested the hypothesis that 5-HT neurons can dampen the effects mediated by mesolimbic DA. For example, it has been shown that pharmacological manipulations that increase extracellular 5-HT attenuate stimulant effects produced by DA release, such as locomotor stimulation and self-administration behavior. Finally, we discuss our recently published data about PAL-287 (naphthylisopropylamine), a novel non-amphetamine DA-/5-HT-releasing agent that suppresses cocaine self-administration but lacks positive reinforcing properties. It is concluded that DA/5-HT releasers might be useful therapeutic adjuncts for the treatment of cocaine and alcohol addiction, obesity, and even attention defi cit disorder and depression. Alcohol , amphetamine , cocaine , dopamine , serotonin , treatment , transporter Corresponding Author: Richard B. Rothman, Clinical Psychopharmacology Section, IRP, NIDA, NIH, PO Box 5180, 5500 Nathan Shock Drive, Baltimore, MD 21224 . Tel: (410) 550-1598 ; Fax: (410) 550-2997 ; E-mail: rrothman@mail.nih.gov
INTRODUCTION
A major goal of this article is to review recent work from our lab that pertains to dual dopamine (DA)/serotonin (5-HT) releasers as potential medications for alcohol and psychostimulant addictions. [1] [2] [3] [4] [5] [6] [7] [8] [9] The term " psychostimulant " refers to drugs that produce a spectrum of effects in humans, including cardiovascular stimulation, mood elevation, and a decreased need for sleep. At higher doses, or after longer periods of use, stimulants can cause a range of disordered thought processes, including severe psychotic episodes. In laboratory animals, psychostimulants increase locomotor activity and are readily self-administered because of their powerful reinforcing properties. Psychostimulants are often described generally as " amphetamine-like, " since amphetamine is the prototypical stimulant agent. Table 1 lists examples of stimulants, and Figure 1 depicts the chemical structures of drugs discussed in this article. It is noteworthy that many of these drugs are useful medications with long histories of effi cacy and safety, whereas others are highly addictive substances [10] [11] [12] that are associated with considerable morbidity and mortality. 12 , 13 In some cases, such as amphetamine, the same drug can be a therapeutic entity or an abused substance, depending upon the context in which the drug is administered.
Most psychostimulants interact with monoamine neurons in the central nervous system (CNS). Neurons that synthesize, store, and release the monoamine transmitters norepinephrine (NE), DA, and 5-HT are widely distributed in the mammalian CNS. These neurons express specialized plasma membrane proteins that function to transport previously released transmitter molecules from the extracellular space back into the cytoplasm. 14 , 15 Substantial evidence has shown that there are distinct transporter proteins expressed by NE neurons (NET), DA neurons (DAT), and 5-HT neurons (SERT). These proteins belong to a superfamily of Na + /Cl --dependent transporters that share genetic, structural, and functional homologies. 16 , 17 Under normal circumstances, the transporter-mediated uptake of monoamine transmitters is the principal mechanism for inactivation of monoaminergic signaling in the brain. The biogenic amine neurotransmitters and their receptors play a critical role in either the E2 pathogenesis or the treatment of a wide range of psychiatric disorders. 18 In general, drugs that target transporter proteins can be divided into 2 classes based on their precise mechanism of action: reuptake inhibitors and substrate-type releasers. Reuptake inhibitors bind to transporter proteins but are not themselves transported. These drugs elevate extracellular transmitter concentrations by blocking transporter-mediated recapture of transmitter molecules from the synapse. Substrate-type releasers bind to transporter proteins and are then transported into the cytoplasm of nerve terminals. " Releasers, " a term used interchangeably with the term " substrates, " elevate extracellular transmitter concentrations by a 2-pronged mechanism: (1) they promote effl ux of transmitter by a process of transporter-mediated exchange, and (2) they increase cytoplasmic levels of transmitter by disrupting storage of transmitters in vesicles via interactions with vesicular monoamine transporter 2 (VMAT 2 ). 19 , 20 The exact mechanism underlying the transporter-mediated exchange mechanism is complex and still under intensive investigation. [21] [22] [23] The interaction with VMAT 2 can increase the pool of neurotransmitter available for release by transporter-mediated exchange. Because substrate-type releasing agents must be transported into nerve terminals to promote transmitter release, reuptake inhibitors can block the effects of releasers.
DUAL-DEFICIT MODEL OF STIMULANT ADDICTION
The initial use of stimulants such as cocaine and methamphetamine produces a " high " or " rush " that is likely caused by elevations in extracellular DA levels in mesolimbic circuits, although some evidence indicates that elevations in extracellular NE may also contribute. 4 , 24 Similarly, alcoholinduced increases in mesolimbic DA are thought to underlie the positive reinforcing effects of this substance. 25 Episodic use of stimulants, especially when they are self-administered via smoking or the intravenous route, can lead to severe addiction in susceptible individuals. The persistent abuse of stimulants and alcohol causes long-term changes in neurochemistry and brain circuitry via processes of synaptic plasticity. [25] [26] [27] Both preclinical and human data suggest that withdrawal from drugs of abuse is associated with impairments in 5-HT neuronal function [28] [29] [30] in addition to the wellaccepted defi cits in DA function. 31 Compelling clinical 
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evidence for 5-HT defi cits in cocaine addiction is the occurrence of psychiatric symptoms resembling major depression following abstinence from binge cocaine use, 31 , 32 coupled with increased prevalence of suicidal ideation and suicide attempts among cocaine addicts. 33 A well-established role of 5-HT dysfunction in mediating depression and suicide 34 suggests that decreased synaptic 5-HT might play a role in cocaine and alcohol withdrawal states. 35 Indeed, the constellation of symptoms often reported by patients withdrawing from stimulant or alcohol use, such as depressed mood, suicidal ideations, obsessive thoughts of using drugs, intense drug craving, anhedonia, increased impulsivity, and susceptibility to drug-related cues presumably refl ects long-term changes in brain function and structure. In particular, evidence points to defi cits in DA and 5-HT neuronal function during withdrawal from alcohol and stimulant abuse. 30 We have proposed a dual-defi cit model of stimulant addiction in which drug-induced DA and 5-HT dysfunction contributes to withdrawal symptoms, drug craving, and relapse. 1 , 30 , 36 , 37 According to the dual-defi cit model, depicted diagrammatically in Figure 2 , decreased synaptic DA during stimulant withdrawal underlies anhedonia and psychomotor retardation, whereas decreased synaptic 5-HT gives rise to depressed mood, obsessive thoughts, and lack of impulse control. Consistent with this model, rats receiving repeated injections of abused stimulants exhibit neurobiological changes similar to those observed in human patients with major depression. 30 , 38-40 If abstinent stimulant addicts exhibit DA and 5-HT defi cits, a logical prediction of the dual-defi cit model would be that pharmacotherapies capable of correcting abnormalities in DA and 5-HT function should be effective in treating stimulant and alcohol dependence.
In agreement with the dual-defi cit hypothesis, drugs that release DA (phentermine, amphetamine) or 5-HT (fenfl uramine) display properties consistent with the effective treatment of substance use disorders. 36 , 41-44 Indeed, administration of DA and 5-HT releasers alone, or in combination, decreases drug-seeking behavior in preclinical models of addiction. Acute and chronic administration of d-amphetamine, a DA-releasing agent, decreases cocaine self-administration behavior in rhesus monkeys. 45 , 46 As illustrated in Figure 3 , the DA-releasing agent phentermine suppresses responding for cocaine without affecting food-reinforced behavior, and this effect is maintained by daily administration of E4 phentermine. 9 These results provide a rationale for using DA-releasing agents as medications for treating cocaine addiction. 47 , 48 Stimulation of 5-HT transmission can reduce drug-seeking behavior as well. Administration of the 5-HT precursor L-tryptophan, which increases brain 5-HT synthesis, to rats decreases self-administration of cocaine 49 and amphetamine. 50 The 5-HT releaser fenfl uramine decreases responding for cocaine in rhesus monkeys. Interestingly, combined administration of phentermine and fenfl uramine produces a 75% decrease in cocaine self-administration in monkeys. 51 The mixture of d-fenfl uramine and phentermine reduces cocaine self-administration by 80% in rats, yet this mixture is not self-administered. 52 The 5-HT-releasing agents suppress cue-elicited cocaine-seeking behavior in rats 53 and decrease cocaine craving in cocaine-dependent patients. 54 These and other fi ndings 36 indicate that combined treatment with DA and 5-HT releasers may have greater therapeutic value than treatment with either drug alone, in terms of decreasing stimulant self-administration and reducing cue-induced relapse. A growing body of evidence shows that DA-/5-HTreleasing agents may provide similar therapeutic benefi ts for alcohol dependence. 41 , 42 , 55 
DUAL DA/5-HT RELEASERS AS AGONIST TREATMENTS
The use of stimulant-like medications to treat stimulant addictions is known as agonist therapy. This strategy involves administering medications that are less potent and less addictive than cocaine or methamphetamine but decrease stimulant abuse because they share neurochemical properties with the illicit drugs. 56 Viewed from this perspective, agonist therapy is like neurochemical " normalization " therapy: by substituting for the abused drug, the treatment drug " normalizes " dysregulated neurochemistry. 5 Neurochemical normalization therapy has generated effective treatments for nicotine dependence 57 and opioid dependence 58 , 59 and has recently been explored for the treatment of cocaine dependence. [60] [61] [62] [63] [64] A major limitation of this approach as applied to stimulant addiction is that candidate medications often exhibit intrinsic abuse liability. 47 One possible advantage of treating stimulant and alcohol dependence with dual DA-/5-HT-releasing agents is that concurrent elevation of extracellular 5-HT can greatly reduce the typical psychomotor actions of DA releasers, including locomotor activity, reward, and self-administration behavior.
Several lines of evidence support the notion that elevations in synaptic 5-HT counteract the stimulant and reinforcing effects mediated by elevations in synaptic DA. 65 , 66 As noted above, L-tryptophan decreases cocaine 49 and amphetamine 50 self-administration in rats. Likewise, pretreatment with 5-HT reuptake inhibitors reduces intravenous cocaine self-administration in rats 67 and squirrel monkeys. 68 Cocaine analogs that have potent 5-HT transporter affi nity 69 support less self-administration behavior than analogs with weak 5-HT transporter affi nity. Moreover, as described in a recent review, agents that broadly activate brain 5-HT systems can reduce self-administration of stimulants and xother drugs of abuse. 70 The " antistimulant " effect of increasing extracellular 5-HT is readily observed after combined administration of 5-HT releasers and DA releasers, or after administration of single agents that release both neurotransmitters. As summarized in Table 2 , drugs that release Combining a DA releaser with a 5-HT releaser (phentermine plus fenfl uramine), or a single molecule that has similar potencies for releasing DA and 5-HT, results in elevation of both extracellular 5-HT and DA. When the elevations in 5-HT are somewhat greater than the elevations in DA, there is minimal locomotor activation, coupled with minimal or no self-administration. The " antireward " effect of increasing extracellular 5-HT is also seen in the conditioned place preference (CPP) assay, shown in Figure 4 , where a low dose of fenfl uramine greatly reduces the positive CPP induced by phentermine. These considerations led us to predict that a single molecule that releases both 5-HT and DA would be able to decrease stimulant self-administration yet have minimal abuse liability. Such an agent would thereby provide the advantages of agonist therapy without the untoward side effects of a potential drug of abuse.
POTENTIAL ADVERSE EFFECTS OF 5-HT RELEASERS
Unfortunately, 5-HT-releasing agents are associated with several adverse effects of their own. 71 Based primarily on experience with fenfl uramine, 3 potentially serious adverse effects need to be addressed when 5-HT releasers are developed as treatment agents: cardiac valvulopathy, serotonergic neurotoxicity, and primary pulmonary hypertension (PPH). The association of fenfl uramine with an increased prevalence of cardiac valve disease led to its withdrawal from the marketplace in September 1997. 72 Recent investigations have demonstrated that norfenfl uramine, the N-deethylated metabolite of fenfl uramine, activates 5-HT 2B receptors on heart valves to stimulate mitogenesis, and this action may represent the principal mechanism underlying cardiac valve disease. [73] [74] [75] The term " 5-HT neurotoxicity, " when used in the present context, refers to the fact that high-dose administration of selective 5-HT releasers (eg, fenfl uramine) often causes persistent depletion of brain tissue 5-HT and SERT binding. A key observation is that not all 5-HT releasers deplete 5-HT. 2 , 76 As shown in Figure 5 , repeated administration of the 5-HT-releasing agent m-chlorophenylpiperazine (mCPP) fails to deplete brain 5-HT, despite producing elevations of extracellular 5-HT comparable to those produced by fenfl uramine. 2 These data indicate that SERT-mediated release of 5-HT is necessary but not suffi cient to produce long-term depletion of brain 5-HT. Increasing evidence indicates that SERT sites are involved in the mechanism by which fenfl uramine increases the risk of developing PPH (for review, see Rothman and Baumann 71 and references therein). For example, medications that increase the risk for PPH have in common the ability to release 5-HT by a SERT-mediated process. On the other hand, not all 5-HT releasers are associated with PPH. The antidepressant trazodone is not associated with PPH, yet its major metabolite, mCPP, is a potent SERT substrate, as noted above. 2 Experimental data from a mouse model of hypoxic pulmonary hypertension suggest that 5-HT 2B receptors may also contribute to the pathogenesis of PPH. 77 The relevance of these fi ndings to drug-induced PPH is not clear, since aminorex, a 5-HT releaser that caused an epidemic of PPH in the 1960s, 78 has minimal activity at 5-HT 2B receptors. Viewed collectively, the available data suggest that it should be possible to develop dual DA/5-HT releasers devoid of fenfl uramine-like adverse effects. In particular, we have suggested that a lead drug molecule should be chemically distinct from the phenylethylamine structure shared by amphetamine-like agents and should lack significant agonist activity at 5-HT 2B receptors. 79
PAL-287, A NON-AMPHETAMINE DA/5-HT RELEASER
Based in part on the above rationale, we sought to identify and characterize a non-amphetamine transporter substrate that would be a potent releaser of DA and 5-HT without affecting the release of NE. After an extensive evaluation of over 350 compounds, we found it virtually impossible to dissociate NE-and DA-releasing properties, perhaps because of phylogenetic similarities between NET and DAT. The fi rst lead compound from our search was PAL-287 (naphthylisopropylamine; see structure in Figure 1 ), a novel non-amphetamine monoamine releaser. 7 The in vitro potency of PAL-287 at releasing tritiated transmitter from DAT, NET, and SERT is 12.6 ± 0.4 nM, 11.1 ± 0.9 nM, and 3.4 ± 0.2 nM, respectively ( Table 2 ). Figure 6 shows that administration of PAL-287 to rats increases extracellular 5-HT and DA in a dose-dependent manner, with larger effects on 5-HT than on DA. Functional studies with cloned human 5-HT 2 receptors reveal that PAL-287 is a full agonist at 5-HT 2B receptors (EC 50 = 40 nM) and 5-HT 2A receptors (EC 50 = 466 nM). The drug is a potent partial agonist at 5-HT 2C receptor sites (EC 50 = 2.3 nM, E MAX = 20%), an effect that suggests possible anorectic actions of PAL-287. 80 The 5-HT 2C agonist activity may also contribute to the minimal reinforcing properties of PAL-287 despite the potent DA-releasing actions of the drug (see Czoty et al 81 for a review). The relatively weak potency at 5-HT 2A and 5-HT 2B receptors, as compared with its activity at SERT, suggests that PAL-287 may not activate 5-HT 2A and 5-HT 2B receptors in vivo.
As reported in Figure 6 , PAL-287 produces minimal ambulation and stereotypy (approximately one third of that produced by (+)-amphetamine) when administered to rats. Repeated high-dose administration of PAL-287 to rats (18 mg/kg intraperitoneally [ip] q 2 hours × 3 doses) fails to affect brain tissue 5-HT levels when assessed 2 weeks after injections, unlike (+)-methamphetamine (6.0 mg/kg ip q 2 hours × 3 doses) and ( ± )-3,4-methylenedioxymethamphetamine (MDMA) (7.5 mg/kg ip q 2 hours × 3 doses), which cause signifi cant 5-HT depletions. The data in Figure 7 show that PAL-287 does not support self-administration behavior, and chronic administration of the drug decreases cocaine self-administration in rhesus monkeys. A dose of 1.0 mg/kg/hr PAL-287 signifi cantly reduces both cocaine-and 
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food-maintained responding; however, the suppression of cocaine self-administration is greater than the reduction in food-maintained responding.
Our results with PAL-287 confi rm the hypothesis that a non-amphetamine substrate at DAT and SERT will release DA and 5-HT from neurons in vivo, be minimally reinforcing, and suppress ongoing cocaine self-administration. PAL-287 displays several desirable qualities for a candidate treatment medication, including minimal locomotor activation, lack of long-term 5-HT neurotoxicity, and low abuse potential. Future studies will be necessary to determine the potential of PAL-287 for increasing the risk for PPH, perhaps by determining its potency at human voltage-gated K + channels. 82 The present data with PAL-287 support the use of monoamine releasers as agonist medications for the treatment of stimulant addictions. A dose of 1.0 mg/kg/hr PAL-287 virtually eliminated cocaine self-administration in rhesus monkeys by the end of the 7-day treatment, although this effect was not entirely selective for cocaine vs food.
We also note that the role of NE in the actions of PAL-287 is an important issue awaiting additional study. 4
CONCLUSIONS
Our fi ndings with PAL-287 in monkeys are similar to the suppression of cocaine self-administration produced by (+)-amphetamine, although amphetamine displays greater selectivity than PAL-287 in reducing cocaine selfadministration as opposed to food-maintained responding. 83 Grabowski et al 61 , 84 showed that a slow-release formulation of (+)-amphetamine is effective in keeping cocaine addicts in treatment and reducing illicit cocaine use. We predict that agents with mixed DA-/5-HT-releasing activity, such as PAL-287, will possess the therapeutic effects of amphetamine-type monoamine releasers, while minimizing the adverse effects associated with the phenylethylamine structure. Based on observations that dual DA/5-HT releasers also suppress alcohol ingestion, 41 , 42 , 55 it is also likely that PAL-287 agents should also be tested as potential treatment agents for alcohol addiction, especially since dual DA/5-HT releasers suppress alcohol withdrawal seizures. 41 Although further work remains to refi ne PAL-287, in particular to reduce its potency at 5-HT 2B receptors, we believe that PAL-287 represents the prototype for a new generation of drugs that enhance biogenic amine release by acting as substrates at multiple biogenic amine transporters. It seems possible that drugs with a similar mode of action will provide neurochemical normalization therapy for the treatment of cocaine and alcohol addiction, and might be useful for treating depression, obsessive-compulsive disorder, attention defi cit disorder, and obesity. . Post hoc analysis was conducted with the Newman-Keuls test. *Indicates signifi cant effect of PAL-287 dose in comparison to control for a given reinforcer, P < .05. ¥ Indicates that food-maintained responding was signifi cantly greater than cocaine-maintained responding at that dose of PAL-287, P < .05. PAL-287 indicates naphthylisopropylamine; inj, injection; FR, fi xed ratio.
